Get started
Award

TrialNet at Stanford University

Description: PUBLIC HEALTH RELEVANCE: Type 1 diabetes mellitus is a serious, chronic, life limiting disease that strikes predominantly in children and adolescents. The TrialNet clinical research network, the focus of the proposal, designs and conducts studies aimed at preventing or delaying the onset or progression of type 1 diabetes, both highly relevant public health goals.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2001-09-29
End date: 2020-04-30
Investigator: DARRELL M WILSON
Institution: STANFORD UNIVERSITY
Field: Medicine
Funded outputs count: 185
Funder award ID: U01DK061042
OpenAlex ID: G584698736
β-Cell Dysfunction Identifies Individuals With Single Autoantibody Positivity at Increased Risk of Type 1 Diabetes Progression
2026 · Emily K. Sims, Lu You, et al. · Diabetes Care
Quantification of Proinsulin in Human Plasma by Proteolysis-Aided Peptide Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry
2026 · Sara K Shijo, Elisha Goonatilleke, et al. · Clinical Chemistry
Islet Autoantibody Patterns Vary by Race and Ethnicity and Area Deprivation Index for Individuals at Risk for Type 1 Diabetes
2026 · Ananta Addala, Susanne Cabrera, et al. · Diabetes Care
PDF
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile
2026 · Laura M. Jacobsen, Dave Cuthbertson, et al. · Diabetes Care
Phase I Clinical Trial of Islet Antigen–Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes
2026 · Carla J. Greenbaum, S. Alice Long, et al. · Diabetes · 3
Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression
2025 · Taylor M. Triolo, Jay M. Sosenko, et al. · Diabetes · 3
Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention
2025 · Lu You, Hemang M. Parikh, et al. · Diabetes Care
PDF
Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort
2025 · Camille Préfontaine, Jasmine Pipella, et al. · Scientific Reports · 6
PDF
Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes
2025 · Alfonso Galderisi, Alice L.J. Carr, et al. · Diabetes · 4
Stage 1 type 1 diabetes memory B lymphocytes transcriptionally differ from healthy controls and harbor insulin-binding specificities
2025 · Lindsay E Bass, Wyatt J McDonnell, et al. · ImmunoHorizons · 2
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes
2025 · Gabriele Sassi, Pierre Lemaitre, et al. · Journal of Clinical Investigation · 4
PDF
Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval
2025 · Emily K. Sims, William E. Russell, et al. · Diabetes · 3
Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study
2025 · Erin L. Templeman, Lauric A. Ferrat, et al. · Diabetes Care · 25
Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies
2025 · Erin L. Templeman, Lauric A. Ferrat, et al. · BMC Medicine · 7
PDF
Genetic Risk and Transition Through Preclinical Stages of Type 1 Diabetes
2025 · Andrea K Steck, Hemang M Parikh, et al. · The Journal of Clinical Endocrinology & Metabolism · 5
Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy
2025 · Sabina Martinenghi, Aurora Merolla, et al. · Diabetologia · 8
PDF
Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes
2025 · Kyle D. Apley, Lindsay E. Bass, et al. · Drug Delivery and Translational Research · 4
Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding
2025 · Laura M. Jacobsen, Jamie L. Felton, et al. · Diabetes Care · 19
PDF
M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy
2025 · Minh V. Le,, Leonard C. Harrison, et al. · Diabetes Care · 4
PDF
The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
2025 · Heba M. Ismail, David Cuthbertson, et al. · Diabetes · 6
PDF
Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes
2025 · Catherine A. Nicholas, Fatima A. Tensun, et al. · Cell Reports · 12
Comparative Analysis of the Sensitivity, Specificity, Concordance, and 5-Year Predictive Power of Diabetes-Related Autoantibody Assays
2025 · Jeffrey P. Krischer, Sarah Muller, et al. · Diabetes · 14
PDF
IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes
2025 · Emily K. Sims, David Cuthbertson, et al. · Diabetologia · 26
Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
2025 · Alfonso Galderisi, Jacopo Bonet, et al. · The Journal of Clinical Endocrinology & Metabolism · 9
A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts
2025 · Jay M. Sosenko, David Cuthbertson, et al. · Diabetes Technology & Therapeutics · 2
PDF
Year
Topic